TYSABRI pregnancy exposure registry

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 04 Jun 2015

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Natalizumab (Primary)
Indications Multiple sclerosis
Focus Adverse reactions
Acronyms TPER; TYGRIS
Sponsors Biogen Idec

Most Recent Events

07 Aug 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
13 Oct 2010 Preliminary results were presented in an abstarct at the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
13 Oct 2010 According to an abstract of preliminary results, presented at the 26th Congress of ECTRIMS, as of 23 February 2010, 198 patients were registered prospectively to TPER, with 148 outcomes reported.

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight